Boot Barn Up Nearly 14%, on Pace for Largest Percent Increase Since May 2025 -- Data Talk
Dow Jones2026/10/29 17:57Boot Barn Holdings, Inc. (BOOT) is currently at $128.93, up $15.63 or 13.8%
--Would be highest close since Sept. 22, 2026, when it closed at $129.28
--On pace for largest percent increase since May 15, 2025, when it rose 16.66%
--Currently up two consecutive days; up 15.44% over this period
--Best two-day stretch since the two days ending May 16, 2025, when it rose 17.97%
--Up 7.02% month-to-date; on pace for best month since April 2026, when it rose 17.14%
--Down 26.94% year-to-date; on pace for worst year since 2022, when it fell 49.19%
--Down 38.01% from its all-time closing high of $207.98 on Dec. 11, 2025
--Down 30.50% from 52 weeks ago (Oct. 30, 2025), when it closed at $185.51
--Down 38.01% from its 52-week closing high of $207.98 on Dec. 11, 2025
--Up 15.44% from its 52-week closing low of $111.69 on Oct. 27, 2026
--Traded as high as $130.66; highest intraday level since Sept. 22, 2026, when it hit $131.80
--Up 15.32% at today's intraday high; largest intraday percent increase since May 15, 2025, when it rose as much as 19.93%
All data as of 1:55:22 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 29, 2026 13:57 ET (17:57 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
